参考文献/References:
[1] Eckler K.Are all estrogens created equal?.Menopause,2004,11(1):7-8.
[2] Secreto G,Zumoff B.Abnormal production of androgens in women with breast cancer.Anticancer Res,1994,14(5B):2113-2117.
[3] Mant C,Cason J.Mouse mammary tumor virus and human breast cancer.Cancer Res,2005,65(3):1112-1113.
[4] Loman N,Johannsson O,Kristoffersson U,et al.Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset a breast cancer.J Natl Cancer Inst.2001,93(16):1215-1223.
[5] Brison O.Gene amplification and tumor progression.Biochim Biophys Acta,1993,1155(1):25-41.
[6] Harish MG,Konda SD,MacMahon H,et al.Breast lesions incidentally detected with CT:what the general radiologist needs to know.Radiographics,2007,27(suppl 1):S37-S51.
[7] 夏良,廖翠微,王玉锦,等.X线摄影和螺旋CT诊断乳腺良恶性肿瘤的评价.放射学实践,2003,18(6):420-421.
[8] Pediconi F,Catalano C,Roselli A,et al.Contrast-enhanced MR mammography for evaluation of the contralateral breast in patients with diagnosed unilateral breast cancer or high-risk lesions.Radiology,2007,243(3):670-680.
[9] 尹波,耿道颖,刘莉.功能磁共振成像在乳腺癌诊断中的应用.国际医学放射学杂志,2009,32(1):28-32.
[10] 杨学伟,杨维良,王秀兰,等.99Tcm-MIBI乳腺显像与乳腺X线照相在乳腺癌诊断中的价值.中国普通外科杂志,2004,13(11):801-803.
[11] 陈璟,吴华,胡健,周健.99Tcm-MIBI显像鉴别乳腺肿物良、恶性及探测腋窝淋巴结转移.放射学实践,2003,18(1):59-61.
[12] Khalkhali I,Villanueva-Meyer J,Edell SL,et al.Diagnostic accuracy of 99Tcm-sestamibi breast imaging:multicenter trial results.J Nucl Med,2000,41(12):1973-1979.
[13] Massardo T,Alonso O,Kabasakal L,et al.Diagnostic value of 99Tcm-methylene diphosphonate and 99Tcm-pentavalent DMSA compared with 99Tcm-sestamibi for palpable breast lesions.J Nucl Med,2002,43(7):882-888.
[14] Lumachi F,Ferretti G,Povolato M,et al.Axillary lymph node metastases detection with 99Tcm-sestamibi scintimammography in patients with breast cancer undergoing curative surgery.Anticancer Res,2007,27(4C):2949-2952.
[15] Tiling R,Stephan K,Sommer H,et al.Tissue-specific effects on uptake of 99Tcm-sestamibi by breast lesions:a targeted analysis of false scintigraphic diagnoses.J Nucl Med,2004,45(11):1822-1828.
[16] Avil N,Dose J,Jänicke F,et al.Metabolic characterization of breast tumors with position emission tomography using F-18 fluorodeoxyglucose.J Clin Oncol,1996,14(6):1848-1857.
[17] 邹海东,马榕,余之刚,等.PET/CT诊断乳腺癌及腋窝淋巴结状态的作用评价.外科理论与实践,2006,11(2):108-111.
[18] Been LB,Elsinga PH,de Vries J,et al.Positron emission tomography in patients with breast cancer using 18F-3’-deoxy-3’-fluorolthymidine (18F-FLT)-a pilot study.Eur J Surg Oncol,2006,32(1):39-43.
[19] Rhodes DJ,O’Connor MK,Phillips SW,et al.Molecular breast imag-ing:a new technique using technetium Tc 99m scintimammography to detect small tumors of the breast.Mayo Clin Proc,2005,80(1):24-30.
[20] Ogston KN,Miller ID,Payne S,et al.A new histological grading system to response of breast cancer to primary chemotherapy:prognostic significance and survival.Breast,2003,12(5):320-327.
[21] 胡军利,向明,王文伟,等.高频超声在乳腺癌新辅助化疗中的监测价值.中国医学影像技术,2007,23(9):1333-1336.
[22] 赵红梅,张恒伟,王雁.应用彩色多普勒超声评价乳腺癌新辅助化疗前后的疗效.中国肿瘤临床与康复,2006,13(2):155-156.
[23] 关晏星,雷秋模,翟伟,等.99Tcm-MIBI显像评价乳腺癌新辅助化疗疗效.中华核医学杂志,2006,26(1):36-38.
[24] 汪晓红,彭卫军,沈坤炜等.fMRI监测乳腺癌新辅助化疗疗效的应用.放射学实践,2007,22(11):1135-1138.
[25] 张晓鹏,李洁,孙应实,等.动态增强磁共振成像对乳腺癌新辅助化疗后病理反应性的术前评价.中国医学科学院学报,2008,30(1):98-103.
[26] Smith IC,Welch AE.Hutcheon AW,et al.Positron emission tomography using 18F-f1uorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy.J Clin Oncol,2000,18(8):1676-1688.
[27] Rousseau C,Devillers A,Sagan C,et al.Monitoring of early response to neoadjuvant chemotherapy in stage Ⅱ and Ⅲ breast cancer by[18F]fluorodeoxyglucose positron emission tomography.J Clin Oncol,2006,24(34):5366-5372.
[28] Emmering J,Krak NC,Van der Hoeven J J,et al.Preoperative 18F-FDGPET after chemotherapy in locally advanced breast cancer:prognostic value as compared with histopathology.Ann Oncol.2008,19(9):1573-1577.
[29] Gennari A,Donati S,Salvadori B,et al.Role of 2-[18F]fluorodeoxyglucose (FDG)positron emission tomography (PET)in the early assessment of response to chemotherapy in metastatic breast cancer patients.Clin Breast Cancer,2000,1(2):156-161.
[30] Cachin F,Prince HM,Hogg A,et al.Powerful prognostic stratification by 18F-fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy.J Clin Oncol,2006,24(19):3026-3031.
[31] Schneider JA,Divgi CR,Scott AM,et al.Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer.J Nucl Med,1994,35(11):1748-1752.
[32] Stafford SE,Gralow JR,Schubert EK,et al.Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy.Acad Radiol,2002,9(8):913-921.
相似文献/References:
[1]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[2]许飞,刘建军,黄钢,等.PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展[J].国际放射医学核医学杂志,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
Xu Fei,Liu Jianjun,Huang Gang,et al.The application of hypoxia imaging with PET in predicting tumor hypoxia and guiding clinical therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
[3]胡伟,赵军.小胶质细胞在AD炎性机制中的作用及其常见PET显像剂的应用进展[J].国际放射医学核医学杂志,2016,40(1):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
Hu Wei,Zhao Jun.Microglia’s Alzheimer disease inflammatory mechanisms and progress of its common application in PET imaging agents[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
[4]张莹莹,王振光,孔艳.PET/CT显像在肺间质纤维化中的应用进展[J].国际放射医学核医学杂志,2016,40(1):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
Zhang Yingying,Wang Zhenguang,Kong Yan.Application advancement on PET/CT in pulmonary interstitial fibrosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
[5]李海峰,张晓军,李云钢,等.国产模块LOOP环改良法合成11C-蛋氨酸[J].国际放射医学核医学杂志,2016,40(2):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
Li Haifeng,Zhang Xiaojun,Li Yungang,et al.Synthesis of 11C-methionine on home-made module by the improved LOOP method[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
[6]杨雷,袁卫红,王家平,等.99Tcm-MIBI显像与钼靶X线对乳腺癌诊断的比较研究[J].国际放射医学核医学杂志,2016,40(2):111.[doi:10.3760/cma.j.issn.1673-4114.2016.02.005]
Yang Lei,Yuan Weihong,Wang Jiaping,et al.Diagnostic value of technetium 99Tcm sestamibi and X-ray mammography in breast cancer: a comparison study[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):111.[doi:10.3760/cma.j.issn.1673-4114.2016.02.005]
[7]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[8]马乐,张万春,李晓敏.乳腺癌前哨淋巴结核素显像新进展[J].国际放射医学核医学杂志,2016,40(2):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
Ma Le,Zhang Wanchun,Li Xiaomin.Evolution of radionuclide imaging of sentinel node lymphscintigraphy in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
[9]李海峰,张晓军,张锦明.多巴胺转运蛋白显像剂11C-β-CFT在帕金森病中的应用研究[J].国际放射医学核医学杂志,2016,40(3):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
Li Haifeng,Zhang Xiaojun,Zhang Jinming.Review of the use of dopamine transporter imaging agent 11C-β-CFT for diagnosing Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
[10]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[11]胡鸿,唐刚华,聂大红.乳腺癌分子显像研究进展[J].国际放射医学核医学杂志,2015,39(1):91.[doi:10.3760/cma.j.issn.1673-4114.2015.01.019]
Hu Hong,Tang Ganghua,Nie Dahong.Progress on molecular imaging of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):91.[doi:10.3760/cma.j.issn.1673-4114.2015.01.019]
[12]李雯,冯彦林.18F-FDG PET/CT评估三阴性乳腺癌新辅助化疗疗效的研究进展[J].国际放射医学核医学杂志,2014,38(3):197.[doi:10.3760/cma.j.issn.1673-4114.2014.03.013]
Li Wen,Feng Yanlin.Advances of assessment with 18F-FDG PET/CT in triple-negative breast cancer during neoadjuvant chemotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):197.[doi:10.3760/cma.j.issn.1673-4114.2014.03.013]
[13]胡梦裳,章斌.PET/CT显像在乳腺癌疗效评价及预后中的作用[J].国际放射医学核医学杂志,2014,38(5):332.[doi:10.3760/cma.j.issn.1673-4114.2014.05.013]
Hu Meng-shang,Zhang Bin.The role of PET/CT imaging in the evaluation of the efficacy and prognosis of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):332.[doi:10.3760/cma.j.issn.1673-4114.2014.05.013]
[14]董佳佳,章斌.多种影像学方法评价乳腺癌新辅助化疗疗效的价值比较[J].国际放射医学核医学杂志,2014,38(6):427.[doi:10.3760/cma.j.issn.1673-4114.2014.06.018]
Dong Jia-jia,Zhang Bin.Comparision on the values of different image modalities in monitoring the response to neoadjuvant chemotherapy in breast cancer patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):427.[doi:10.3760/cma.j.issn.1673-4114.2014.06.018]
[15]袁建伟,杨劼,贺小红,等.乳腺癌18F-FDG PET/CT和3.0T MRI联合显像评分与Ki-67表达水平的相关性分析[J].国际放射医学核医学杂志,2013,37(2):84.[doi:10.3760/cma.j.issn.1673-4114.2013.02.006]
YUAN Jian-wei,YANG Jie,HE Xiao-hong,et al.Correlation between combined imaging modalities of 18F-FDG PET/CT and 3.0T MRI and expression of Ki-67 in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):84.[doi:10.3760/cma.j.issn.1673-4114.2013.02.006]
[16]袁建伟,杨劼,贺小红,等.18F-FDG PET/CT与3.0T MRI联合显像在乳腺癌原发病灶诊断中的价值[J].国际放射医学核医学杂志,2013,37(4):199.[doi:10.3760/cma.j.issn.1673-4114.2013.04.003]
YUAN Jian-wei,YANG Jie,HE Xiao-hong,et al.Diagnosis value of 18F-FDG PET/CT and 3.0T MRI combined imaging in detecting the primary focus of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):199.[doi:10.3760/cma.j.issn.1673-4114.2013.04.003]
[17]林美福,陈文新,周硕,等.18F-FES PET/CT显像在雌激素受体阳性乳腺癌诊疗中的初步应用[J].国际放射医学核医学杂志,2013,37(4):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
LIN Mei-fu,CHEN Wen-xin,ZHOU Shuo,et al.Application of 18F-FES PET/CT in diagnosis and endocrine therapy of patients with estrogen receptorpositive breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
[18]鲁胜男,冯彦林.乳腺癌新辅助化疗过程中18F-FDG PET-CT与化疗前Ki-67、COX-2表达的相关性研究[J].国际放射医学核医学杂志,2011,35(4):238.[doi:10.3760/cma.j.issn.1673-4114.2011.04.011]
LU Sheng-nan,FENG Yan-lin.The correlation analysis between 18F-FDG PET-CT in breast cancer with neoadjuvant chemotherapy and the expression of Ki-67 and COX-2 before neoadjuvant chemotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(4):238.[doi:10.3760/cma.j.issn.1673-4114.2011.04.011]
[19]张亶,章斌,邓胜明,等.18F-FDG PET/CT在乳腺癌术后随访中的价值[J].国际放射医学核医学杂志,2017,41(3):159.[doi:10.3760/cma.j.issn.1673-4114.2017.03.001]
Zhang Dan,Zhang Bin,Deng Shengming,et al.Clinical value of 18F-FDG PET/CT in follow-up of postoperative breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(4):159.[doi:10.3760/cma.j.issn.1673-4114.2017.03.001]